Abstract: Synthesis of a novel Combretastatin A-4 analogue using Schiff's reaction of benzil and 4-aminoantipyrine has been achieved under solvent free conditions. The structure of compound was examined spectroscopically and confirmed from single crystal diffraction studies. The synthesized Combretastatin A-4 analogue was investigated for its DNA binding ability as the plausible mechanism for its antitumor activity. The binding propensity of the synthesized compound with calf-thymus (CT) DNA was monitored with absorption and emission spectrophotometric titrations. The calculations predict a binding constant of 7.24 × 10 4 for the complex of the synthesized compound with CT DNA which is comparable in magnitude to that of DNA binding of bactericidal drug enoxacin and typical intercalation indicator ethidium bromide (EB). Competitive binding studies of the synthesized compound with EB using fluorescence titration reveal that it displaces the DNA-bound EB and binds in intercalative mode which was further supported by circular dichroism (CD) spectroscopy. The probable site and binding energy of the compound with DNA was further theoretically investigated by molecular docking studies. The significant DNA binding ability of the synthesized Combretastatin A4 analogue as revealed from this study could be related to the anticancer activity of the Combretastatin A4.
INTRODUCTION
YNTHESIS of specially designed compounds for specific applications through an environmentally benign methodology is one of the contemporary challenges. [1] 4-Aminoantipyrine belongs to the class of phenazones, a predominantly useful heterocyclic compounds, known for their significant role in organic synthesis [2] and diverse biological activity. [3] Benzil (an aromatic 1,2 diketone) is a common building block in organic synthesis which is also reported to be a strong inhibitor of mammalian carboxylesterase enzymes. [4] Recently metabolic enzyme expression has been linked to metabolic alterations which are being regarded as a hallmark of cancer. [5] In continuation of our work on anti cancer compounds [6] [7] [8] [9] [10] a schiff base of benzil and 4-aminoantipyrine -the two privileged molecules of drug development was designed. The motivation for selecting benzil amongst a plethora of aromatic 1,2 diketones is its prominent resemblance to anticancer natural product Combretastatin ( Figure 1 ) which has served as a fundamental scaffold for the synthesis of large number of compounds with antitumor activity. [11, 12] The presence of two aryl rings with hydrogen bonding groups and the restricted rotation about the olefinic bridge in Combretastatin is considered crucial for their anticancer activity. [13] The benzil moiety in the synthesized schiff base (compound 1) has two aryl rings, hydrogen bonding carbonyl group and restricted rotation due to the bulky antipyrine group, hence the synthesized compound 1 has a close resemblance to the pharmacophore of the Combretastatin. Since DNA is considered to be a primary target of most of the anticancer compounds and essentially based on the idea that compounds with planar aromatic rings are known to be its intercalators [14] an investigation of DNA binding propensity of synthesized compound was evaluated using different biophysical methods. [15] Even though DNA binding ability of a vast number of compounds has been reported, [16, 17] the point of interest in this study is metal free DNA binding ability of a natural product analogue synthesized from two bioactive constituents.
EXPERIMENTAL

Materials
All reagents and solvents used (4-aminoantipyrine, benzil, dichloromethane, methanol) were of analytical grade obtained from Sigma-Aldrich Chemicals Pvt. Ltd. and were used without further purification. The calf Thymus DNA was purchased from Bangalore Genei, (India). Silica gel coated aluminum plates were used for TLC monitoring of reactions. The synthesized Schiff base compound was soluble at room temperature in Tris-HCl buffer (pH = 7.2) in presence of 1 % DMSO solution. All the experimental solutions and dilutions of compound 1 were done using the Tris-HCl buffer (pH = 7.2) in presence of 1 % DMSO solution. The stock solution of CT-DNA was prepared in Tris-HCl buffer (pH = 7.2) stored at 4 °C and consumed within 2 days.
Instrument and physical measurements
The IR spectrum was recorded as KBr pellet on Shimadzu IR-408 Perkin-Elmer 1800 (FTIR) spectrophotometer and the values are given in cm -1 . Elemental analysis (C, H, N) was performed using Carlo Erba analyzer model 1108. An HR ESI-MS spectrum was recorded on G6540-UHD LC/MS Q-TOF (Agilent Technologies). 1 H NMR spectra were recorded on Bruker-Avance DPX FT-NMR 400 MHz spectrometer with TMS as an internal standard. The single crystal X ray structure was obtained using X'calibur CCD area-detector diffractometer. The UV-Vis measurements were recorded on a 177 Beckman DU 40 Spectrophotometer (USA) using a cuvette of 1 cm path length. Fluorescence measurements were recorded on a Shimadzu 184 Spectrofluorimeter -5000 (Japan) spectra in the range of 200-330 nm around 25 °C. The CD spectra were collected using a Jasco J-815 Circular dichroism (CD) Spectropolarimeter. The geometries were optimized with the Gaussian 03 quantum chemistry package using Becke's three parameter hybrid functional (B3LYP) and the 6-311G (d,p) ++ basis set. The rigid molecular docking studies were performed using HEX 6.1 software. The Hex 6.1 performs protein docking using Spherical Polar Fourier Correlations, which needs the ligand and the receptor input in PDB format.
General Procedure
The compound 1 was synthesized by fusion of 1:1 molar ratio of 4-aminoantipyrine and benzil. The solid 4-aminoantipyrine was first melted over silicone oil bath maintained around 110 °C followed by slow addition of solid benzil (m.p. 97 °C) to the molten state of 4-aminoantipyrine. The reaction mixture was stirred over a magnetic stirrer for 1 h and the progress of reaction was monitored using TLC. After completion of reaction yellow colored solid product got separated, which was filtered, air dried and recrystallized from methanol and dichloromethane (4 : 1) 
Crystal Structure Determination and Refinement
The X-ray intensity data of 8516 reflections (of which 4083 unique) were collected on X'calibur CCD area-detector diffractometer equipped with graphite monochromated Mo-Kα radiation (λ = 0.71073 Å). The dimension of crystal used for data collection was 0.30 × 0.20 × 0.20 mm. The cell dimensions were determined by least-squares fit of angular settings of 2842 reflections in the θ range 3.81 to 28.85 °. The intensities were measured by ω scan mode for θ ranges 3.56 to 26.00 °. 2755 reflections were treated as observed: I > 2ζ(I). The structure was solved by direct methods using SHELXL 97. All non-hydrogen atoms of the molecule were located in the best E-map. Full-matrix least-squares refinement was carried out using SHELXL 97. The final refinement cycles converged to R = 0.0441 and wR (F 2 ) = 0.1113 for the observed data. 
Preparation of DNA Stock Solution
The stock solution of DNA was prepared by dissolving CT DNA in Tris-HCl buffer (30 mM, pH = 7.2). The purity of DNA was verified by monitoring the ratio of absorbance at 260 nm to that at 280 nm, which was in the range of 1.8-1.9. The concentration of the DNA was determined spectrophotometrically using ε = 6600 mol L -1 cm -1 . [18] 
Absorption Spectrometry
The absorbance value of the compound 1 was recorded in the absence and presence of DNA in the range of 225-550 nm. The reference solution was the corresponding Tris-HCl buffer solution. While measuring the absorption spectra, equal amount of DNA was added to both the compound and reference solutions to eliminate the absorbance of DNA itself.
Emission Spectroscopy
The binding constants Kb of the compound (1) with DNA was obtained by the fluorescence titration method. The fluorescence quenching with increasing concentration of DNA was recorded after exciting the compound solution at 290 nm, using 10/10 nm slit widths.
Circular Dichroism (CD) Studies
The CD spectra were recorded in the region of 330-200 nm with a scan speed of the 200 nm/min in a cuvette of 2 mm path length. Three scans were recorded and averaged.
Viscosity Studies
The viscosity measurements were carried out using Oswald capillary viscometer. The flow time was measured with a digital stopwatch, and each sample was tested three times to get an average calculated time. The data were presented as (η/η0) ⅓ versus concentrations of DNA/compound 1 a ratio where η is the viscosity of the solution in the presence of a compound 1; η0 is the viscosity of the DNA solution only.
Molecular Docking Experiments
The rigid molecular docking studies were performed using HEX 6.1 software. The crystal structure of the B-DNA dodecamer d(CGCGAATTCGCG)2 (PDB ID: 1BNA) was downloaded from the protein data bank. The energy optimized structure of compound 1 was used for the docking study. Visualization of the docked pose has been done by using PyMol (http://pymol.sourceforge.net/) molecular graphic program.
RESULTS AND DISCUSSION
The conventional synthesis employs refluxing reactant mixtures in high boiling organic solvents, followed by extensive chromatographic workup of purification and re-crystallization. At present environmentally benign synthetic methods are receiving considerable attention and solvent-free protocols are in demand. While embracing the principles of green chemistry, [19] we attempted a solvent free target synthesis, of a hitherto unknown compound 1. It was synthesized by condensing of equimolar quantities of 4-amino antipyrine and benzil as shown in Scheme 1. The synthesis involves a one pot, single step, solvent free reaction using non-conventional fusion method in which the reactant with higher melting point (4-aminoantipyrine, m.p. 110 °C) was first liquefied (melted) and the other with lower melting point (benzil, 97 °C) was added to the molten state of former. Thus, equimolar amounts of 4-aminoantipyrine and benzil were condensed under solvent less conditions at 110 °C in a silicone oil bath and the reaction mixture was magnetically stirred for 1 h. The compound 1 was crystallized by s low solvent evaporation method using methanol and dichloromethane (4 : 1) mixture. The structure of the synthesized compound 1 was elucidated by IR, 1 H NMR, Mass spectrometry and Elemental (CHN) analysis, which was also unambiguously confirmed through single crystal X-ray crystallographic study. An ORTEP view of the compound with atomic labeling is shown in (Figure 2 ). The geometry of the molecule was calculated using the WinGX, PARST and PLATON softwares. The extended structure of the compound 1 shows weak intermolecular interactions like π-π stacking, C-H-π, C-H-O and C-H-N type intermolecular interactions (Figure 3) . The crystallographic data is summarized in Table 1 . The measured π-π distances of 3.704 and 3.253 Å respectively suggests π-π stacking and C-H-π interaction. [20, 21] The distances of 2.614 and 2.734 Å respectively indicate a good hydrogen bonding of phenyl hydrogen with carbonyl oxygen and nitrogen atoms in compound 1.
DNA binding studies ABSORPTION SPECTRAL STUDIES
The Uv-visible absorption spectra of compound 1 exhibits intense absorption bands at 290 nm and a shoulder at 400 nm attributed to π-π* and nπ* intraligand transition, respectively. The hypochromism or decrease in absorption intensity of the compound 1 observed on gradual addition of CT DN A (0.00-6.50 × 10 -5 mol L -1 ) to its fixed concentration(1.11 × 10 -4 mol L -1 ) (Figure 4) , was attributed to interaction of its π* molecular orbitals with the π-orbitals of the DNA base pairs, resulting in a decreased π-π* transition probability and hence hypochromism. [22] The binding constant Kb quantifying binding propensity of compound 1 with CT DNA, was obtained from the change in the absorbance spectra with increasing concentrations of CT DNA. The binding constant of 7.24 × 10 4 mol L -1 was calculated from the ratio of slope to the intercept in the inset plot of ( Figure  4 ) using Wolfee-Shimmer equation. [23] ) (
where [DNA] is the concentration of DNA in base pairs, and εa is the apparent extinction coefficient (Aabs / [compound 1], εf is the extinction coefficient of the compound 1 when free in solution and εb is its extinction coefficient when fully 
EMISSION SPECTRAL STUDIES
The compound 1 on excitation at 290 nm emits at 374 nm in the absence of CT DNA. The fluorescence intensity increased with no apparent change in shape and the slight change in position of the emission band (4 nm) on gradual addition of CT DNA (0.00-3.0 × 10 -5 mol L -1 ) to a fixed concentration of compound 1 (1.0 × 10 -5 mol L -1 ) ( Figure 5 ). The hyperchromism in fluorescence intensity of the compound 1 establishes its binding interaction with CT-DNA most probably due to the inaccessibility of solvent water molecules to reach the hydrophobic environment inside the DNA helix and the restricted mobility of the compound at the binding site leading to a decrease in vibrational mode of relaxation. [24] The binding constant value of 7.29 × 10 4 mol L -1 determined from the Scatchard equation [25] depicts the significant interaction between the compound 1 and CT DNA in comparison to the reported binding constant (6.58 × 10 4 mol L -1 ) of a well known DNA intercalator ethidium bromide. [26] COMPETITIVE DNA-BINDING WITH ETHIDIUM BROMIDE (EB) Ethidium bromide (EB, 3,8-diamino-5-ethyl-6-phenyl-phenanthridinium bromide) is a typical intercalator. A competitive binding experiment of compound 1 with EB was carried out to ascertain its intercalative mode of DNA interaction. EB on chelation with DNA gives an intense fluorescence however when freed from DNA, EB does not show any noticeable emission. In the competitive binding experiments, the emission spectra of EB-DNA adduct at 595 nm (λex = 332 nm) in the absence and presence of compound 1 have been recorded. With increasing addition of compound 1 to EB-DNA adduct from the ratio of 1 : 1 to 5 : 1, a decrease in the emission intensity of EB-DNA system was observed indicating competition between EB and compound 1 towards CT-DNA (Figure 6 ). The significant quenching of EB-DNA fluorescence suggests that compound 1 displaces EB from the EB-DNA complex and thus interacts with CT DNA in the intercalative mode at the similar binding site. The fluorescence quenching data were analyzed to obtain the quenching constant using Stern-Volmer equation,
Where F0 and F denote the steady-state fluorescence intensities in the absence and presence of the quencher (compound 1), respectively, KSV is the Stern-Volmer quenching constant and [Q] is the concentration of the quencher. The [Eq. (2)] was applied to determine KSV by linear regression of a plot of (F0 / F) -1 versus concentration of compound 1.
The Ksv value for the compound 1 was found to be 2.88 × 10 4 mol L -1 which is consistent with the electronic absorption results. Comparing the intercalative binding potential of compound 1 with a well known anti-inflammatory drug Naproxen [27] reveals that it brings more quenching of EB-DNA fluorescence even at a lower concentration than naproxen, which confirms the good intercalative binding of compound 1.
CIRCULAR DICHROISM (CD) STUDIES
The covalent binding and intercalation with a drug influence the tertiary structure of DNA and lead to changes in its circular dichroism (CD) spectra. [28] We used CD spectroscopy to identify any change in the structure of the CT DNA upon binding with compound 1. The CD spectrum of CT DNA in Tris-buffer at pH = 7.2 ( Figure 7) , depicts a positive absorption band at 275 nm (band I) and, negative absorption (band II) at 245 nm due to π-π base stacking and right hand helicity respectively, which is consistent with the characteristic B conformation of DNA. [29] With the sequential addition of compound 1 (0.4 -2.4 × 10 -5 mol L -1 ) to a fixed concentration of DNA (2.0 × 10 -5 mol L -1 ), the intensity of 275 nm band got increased while that of 245 nm band went down (from -2 to -6). The changing intensities of two bands result in the formation of isodichroic point at 260 nm suggesting single complex formation between CT-DNA and compound 1. The change in the ellipticity at 275 nm can be explained on the basis of disruption of the stacked bases in order to maximize intercalation of the compound 1 with CT DNA. The change at 245 nm occurs due to change in the hydration layer of DNA, which in turn affects the helicity of DNA. Thus the type of changes in the CD spectra reflect base stacking interactions through intercalation of compound 1. [30] A slight increase in negativity of the band at 211 nm can be due to a partial B to C-DNA conformational transition of compound 1-DNA adduct as recently reported by Marty et al. [31] VISCOSITY STUDIES In classical intercalation the DNA helix lengthens as the base pairs are separated to accommodate the bound ligand leading to increased DNA viscosity. Whereas, a partial, nonclassical ligand intercalation causes a bend in DNA helix reducing its effective length and thereby its viscosity. [32] A plot of relative viscosities (η/η0) 1/3 versus [compound 1] / [DNA] was obtained to study any change in viscosity of DNA solution in presence of the increasing molar ratios of compound 1 to DNA. As illustrated in Figure 8 , on increasing the molar ratios of the compound 1 to DNA (0.0, 0.2, 0.4, 0.6, 0.8, and 1.0), the relative viscosity of compound-DNA increases steadily, which proves that the compound binds to CT DNA by intercalation. The increase in relative viscosity upon addition of compound 1 to CT DNA solution, causes the axial length of the DNA to increase, which corroborates the intercalating tendency of compound 1.
MOLECULAR DOCKING STUDIES
Computational studies through molecular docking are an attractive tool to probe the mechanistic details [33] and mode of interaction between biopolymers and bioactive compounds. Docking studies were attempted to establish the type and the magnitude of interaction between the compound 1 and the CT DNA. In our experiments rigid molecular structure of DNA duplex with a sequence d(CGCGAAT TCGCG)2 dodecamer (PDBID : 1BNA) was taken, the finest fit orientation, and the lowest energy docked structure was analyzed. The study revealed that, initially compound 1 interacts with DNA via an electrostatic mode involving outside edge stacking interactions with the oxygen atom of the phosphate backbone of DNA. The docked structures shown in Figure 9 corroborate well with the experimental results and clearly indicate that the compound 1 fits snugly into the curved contour of the targeted DNA in the minor groove and is situated within a G-C rich region, thus leading to Van der Waals interaction and hydrophobic contacts with the DNA functional groups that define the groove. [34] In addition to this the phenyl ring of the compound 1 is arranged in an intercalative manner between the G10A and C11A of strand A of the DNA double helix. In this configuration, the N14 of the compound remains inclined towards the phosphodiester bond of DNA and hence the possibility of hydrogen bonding cannot be ruled out. The resulting relative binding energy of docked compound-DNA complex was found to be 226.52 kJ mol −1 . High value of the binding energy indicates π-π type of possible interaction between the phenyl ring of the compound 1 and the nucleotide base pairs of DNA in addition to the electrostatic and Vander Waals interaction. [35] From the docking study, it can be concluded that binding studies of such type of molecules with DNA is credible and further work in this direction, is in progress.
CONCLUSIONS
In summary, a novel Combretastatin A4 analogue, compound 1, was synthesized under solvent free conditions using benzil and 4-aminoantipyrine. The compound 1 was spectroscopically examined and structurally characterized by single crystal X ray diffraction study. The CT DNA binding propensity of the compound 1 was investigated by different biophysical methods of DNA binding (fluorescence, electronic absorption, ethidium bromide replacement, CD spectroscopy, viscosity measurement and molecular docking studies). The DNA binding protocols undertaken in the present work were in agreement, with the primary intercalative mode of DNA binding for compound 1. The significant DNA binding ability of compound 1 suggests, the possibility of DNA binding as the plausible mechanism of the Combretastatin anticancer activity. Furthermore, studies aimed at the targeted syntheses of electronically delocalized and sterically pre-organized Combretastatin analogues for exploration as DNA target agents and in the development of new cancer therapeutics is underway in our laboratory.
